Moderna says it is not abandoning its deal with Lonza.
Copyright 2020 The Associated Press. All Rights Reserved.
Despite production of mRNA for the Covid-19 vaccine ending at the Lonza site in Visp, Moderna is maintaining its strategic partnership with the Valais company, assures the boss of the American group. This ten-year partnership was signed in 2020.
“We will discuss possible collaborations as our messenger RNA portfolio materialises,” declared Moderna’s CEO, Stéphane Bancel, in an interview with Le Temps.
He explains that Moderna is “right-sizing its industrial footprint and supply base to accelerate its gross margin expansion toward its long-term goal of 75-80%.” Demand for the vaccine has fallen by 66%, he notes.
The company based in Cambridge, near Boston, in the United States state of Massachusetts plans to absorb demand for mRNA at its Norwood site over the next two years.
In 2025, Moderna plans to expand its capabilities at its new mRNA manufacturing facilities in the United Kingdom, Canada and Australia. Only the manufacturing partnership with Rovi in Spain will be maintained. “At the beginning of this year, we opened a new centre of excellence in Madrid,” notes Stéphane Bancel.
This centre allows analytical tests to be carried out to certify batches of mRNA vaccines for markets outside the United States, he adds. “It makes Spain the largest production centre covering all stages of the Moderna vaccine production chain outside the United States.”
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
This content was published on
Switzerland remains by a large margin the European champion of train travel, both in terms of the number of journeys per person and the number of kilometres travelled. Switzerland remains by a large margin the European champion of train travel, both in terms of the number of journeys per person and the number of kilometres travelled. Switzerland remains by a large margin the European champion of train travel, both in terms of the number of journeys per person and the number of kilometres travelled.
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Lonza to stop producing Moderna Covid-19 vaccine
This content was published on
Swiss pharmaceutical supplier Lonza will stop production of the Covid-19 vaccine for Moderna at its Visp site in the third quarter.
Biotech firm Lonza to invest CHF500 million in new Swiss plant
This content was published on
The company has announced plans to build a large-scale, commercial drug product fill and finish facility in northern Switzerland.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.